Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment
Abstract Teprotumumab (TPT) is a type I insulin-like growth factor receptor inhibitor, marketed as Tepezza; recently USFDA approved it for the treatment of thyroid eye disease (thyroid-associated ophthalmopathy (TAO), Graves ophthalmopathy/orbitopathy) in the USA. It is a monoclonal antibody although it was initially developed in collaboration with Genmab and Roche for the treatment of the tumour, but later it was investigated by River Vision Development Corporation and Horizon Therapeutics for its ophthalmic use. The drug has been designated as an orphan drug, breakthrough designation and fast-track designation. This review summarizes the milestones in the research and development including ongoing, clinical trial of TPT till now, foremost to this primary approval for thyroid-associated ophthalmopathy (TAO)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
International ophthalmology - 41(2021), 4 vom: 22. Jan., Seite 1549-1561 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ali, Faraat [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Graves disease |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s10792-021-01706-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2124844652 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2124844652 | ||
| 003 | DE-627 | ||
| 005 | 20230505093215.0 | ||
| 007 | tu | ||
| 008 | 230505s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10792-021-01706-3 |2 doi | |
| 035 | |a (DE-627)OLC2124844652 | ||
| 035 | |a (DE-He213)s10792-021-01706-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00$jMedizin: Allgemeines |2 bkl | ||
| 100 | 1 | |a Ali, Faraat |e verfasserin |0 (orcid)0000-0002-1438-4223 |4 aut | |
| 245 | 1 | 0 | |a Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature 2021 | ||
| 520 | |a Abstract Teprotumumab (TPT) is a type I insulin-like growth factor receptor inhibitor, marketed as Tepezza; recently USFDA approved it for the treatment of thyroid eye disease (thyroid-associated ophthalmopathy (TAO), Graves ophthalmopathy/orbitopathy) in the USA. It is a monoclonal antibody although it was initially developed in collaboration with Genmab and Roche for the treatment of the tumour, but later it was investigated by River Vision Development Corporation and Horizon Therapeutics for its ophthalmic use. The drug has been designated as an orphan drug, breakthrough designation and fast-track designation. This review summarizes the milestones in the research and development including ongoing, clinical trial of TPT till now, foremost to this primary approval for thyroid-associated ophthalmopathy (TAO). | ||
| 650 | 4 | |a Graves disease | |
| 650 | 4 | |a Thyroid eye disease | |
| 650 | 4 | |a R1507 | |
| 650 | 4 | |a RV001 | |
| 650 | 4 | |a Teprotumumab | |
| 650 | 4 | |a Tepezza | |
| 650 | 4 | |a IGF-1R | |
| 650 | 4 | |a Thyroid-associated ophthalmopathy | |
| 700 | 1 | |a Chorsiya, Anushma |4 aut | |
| 700 | 1 | |a Anjum, Varisha |4 aut | |
| 700 | 1 | |a Ali, Asad |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International ophthalmology |d Springer Netherlands, 1978 |g 41(2021), 4 vom: 22. Jan., Seite 1549-1561 |w (DE-627)168656949 |w (DE-600)800087-6 |w (DE-576)016142098 |x 0165-5701 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:4 |g day:22 |g month:01 |g pages:1549-1561 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10792-021-01706-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.00$jMedizin: Allgemeines |q VZ |0 106409646 |0 (DE-625)106409646 |
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 4 |b 22 |c 01 |h 1549-1561 | ||